Huadong Medicine Co., Ltd
000963
Peringkat dalam Saham
#2704
Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in... Huadong Medicine Co., Ltd is a leading pharmaceutical enterprise based in China, primarily focused on the creation, production, and distribution of a wide variety of medicinal products. Its extensive product catalog encompasses traditional Chinese patent medicines, immunosuppressive agents, endocrine treatments, digestive system remedies, cancer therapeutics, cardiovascular medications, and antibiotics. The company also supplies medical devices and offers solutions in the field of aesthetic medicine. Noteworthy product lines include gastrointestinal agents and Active Pharmaceutical Ingredients (APIs). Beyond its core pharmaceutical activities, Huadong Medicine is involved in the manufacturing and management of both traditional Chinese and Western raw medicines, prepared formulations, and health supplements. Its operations extend to the wholesale trade of Traditional Chinese Medicine (TCM) ingredients, prepared TCM decoction pieces, and various chemical preparations, complemented by warehousing and logistical services. A significant area of focus for the company is the research, development, manufacturing, and commercialization of aesthetic medicine products. Established in 1993, Huadong Medicine Co., Ltd maintains its corporate headquarters in Hangzhou, China.
Harga Saham
$3.89
Kapitalisasi Pasar
$6.83B
Perubahan (1 hari)
-2.22%
Perubahan (1 tahun)
-30.58%
Negara
CN
Perdagangan Huadong Medicine Co., Ltd (000963)
Kategori
Healthcare
Rasio P/E untuk Huadong Medicine Co., Ltd (000963)
Rasio P/E per October 2026 TTM: 13.20
Menurut laporan keuangan dan harga saham terbaru dari Huadong Medicine Co., Ltd, rasio P/E saat ini (TTM) adalah 13.20. Pada akhir 2024, perusahaan memiliki rasio P/E sebesar 17.26.
Riwayat rasio P/E untuk Huadong Medicine Co., Ltd dari 2001 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 13.20 | -34.76% |
| 2025 | 20.23 | 17.21% |
| 2024 | 17.26 | -32.53% |
| 2023 | 25.58 | -21.93% |
| 2022 | 32.77 | 7.21% |
| 2021 | 30.56 | 85.43% |
| 2020 | 16.48 | 8.68% |
| 2019 | 15.16 | -1.40% |
| 2018 | 15.38 | -48.02% |
| 2017 | 29.59 | 23.15% |
| 2016 | 24.02 | -25.85% |
| 2015 | 32.40 | 7.18% |
| 2014 | 30.23 | -13.27% |
| 2013 | 34.85 | 10.76% |
| 2012 | 31.47 | 4.08% |
| 2011 | 30.23 | -32.86% |
| 2010 | 45.02 | 112.35% |
| 2009 | 21.20 | -23.18% |
| 2008 | 27.60 | -37.29% |
| 2007 | 44.01 | 123.08% |
| 2006 | 19.73 | 0.92% |
| 2005 | 19.55 | -56.95% |
| 2004 | 45.41 | -0.01% |
| 2003 | 45.41 | 52.16% |
| 2002 | 29.84 | 15.93% |
| 2001 | 25.74 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 23.30 | 76.53% |
DE
|
|
| 26.92 | 103.95% |
DE
|
|
| 55.58 | 321.10% |
JP
|
|
| 61.13 | 363.20% |
CH
|
|
| 34.87 | 164.24% |
IN
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.